Targeting CD44+ cells demonstrated higher anti-proliferative activity in-vitro compared to the anti-tumor drug SN38 when used against colon, gastric, breast, esophageal, lung, and ovarian cancer cells28, 29. This evidence concerns the gene CD44 and ovarian cancer.